With the advent of BCR-ABL-targeted tyrosine kinase inhibitors (TKIs), CML has become a chronic but manageable disease, but due to the presence of persistent leukemia stem cells (LSCs), all CML patients must receive lifelong treatment [122,123,124]. Here, ABL1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.